These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 38433091)

  • 1. Omission of Breast Surgery in Predicted Pathologic Complete Response after Neoadjuvant Systemic Therapy: A Multicenter, Single-Arm, Non-inferiority Trial.
    Jung JJ; Cheun JH; Kim SY; Koh J; Ryu JM; Yoo TK; Shin HC; Ahn SG; Park S; Lim W; Nam SE; Park MH; Kim KS; Kang T; Lee J; Youn HJ; Kim YS; Yoon CI; Kim HK; Moon HG; Han W; Cho N; Kim MK; Lee HB
    J Breast Cancer; 2024 Feb; 27(1):61-71. PubMed ID: 38433091
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intelligent Vacuum-Assisted Biopsy to Identify Breast Cancer Patients With Pathologic Complete Response (ypT0 and ypN0) After Neoadjuvant Systemic Treatment for Omission of Breast and Axillary Surgery.
    Pfob A; Sidey-Gibbons C; Rauch G; Thomas B; Schaefgen B; Kuemmel S; Reimer T; Hahn M; Thill M; Blohmer JU; Hackmann J; Malter W; Bekes I; Friedrichs K; Wojcinski S; Joos S; Paepke S; Degenhardt T; Rom J; Rody A; van Mackelenbergh M; Banys-Paluchowski M; Große R; Reinisch M; Karsten M; Golatta M; Heil J
    J Clin Oncol; 2022 Jun; 40(17):1903-1915. PubMed ID: 35108029
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selective Avoidance of Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy in Human Epidermal Growth Factor 2-Positive/Triple-Negative Breast Cancer Patients With Excellent Response.
    Ryu JM; Lee H; Han W; Lee HB; Ahn SG; Kim HJ; Park HS; Choi JS; Kim H; Cho WK; Lee JE
    J Breast Cancer; 2024 Apr; 27(2):130-140. PubMed ID: 38685868
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Eliminating Breast Surgery for Invasive Cancer with Exceptional Response to Neoadjuvant Systemic Therapy: Prospective Multicenter Clinical Trial Planned Initial Feasibility Endpoint.
    Johnson HM; Valero V; Yang WT; Smith BD; Krishnamurthy S; Shen Y; Lin H; Lucci A; Rauch GM; Kuerer HM
    J Am Coll Surg; 2023 Jul; 237(1):101-108. PubMed ID: 36856291
    [TBL] [Abstract][Full Text] [Related]  

  • 5. De-ESCAlating RadioTherapy in breast cancer patients with pathologic complete response to neoadjuvant systemic therapy: DESCARTES study.
    van Hemert AKE; van Olmen JP; Boersma LJ; Maduro JH; Russell NS; Tol J; Engelhardt EG; Rutgers EJT; Vrancken Peeters MTFD; van Duijnhoven FH
    Breast Cancer Res Treat; 2023 May; 199(1):81-89. PubMed ID: 36892723
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Eliminating breast surgery for invasive breast cancer in exceptional responders to neoadjuvant systemic therapy: a multicentre, single-arm, phase 2 trial.
    Kuerer HM; Smith BD; Krishnamurthy S; Yang WT; Valero V; Shen Y; Lin H; Lucci A; Boughey JC; White RL; Diego EJ; Rauch GM;
    Lancet Oncol; 2022 Dec; 23(12):1517-1524. PubMed ID: 36306810
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Clinical Feasibility Trial for Identification of Exceptional Responders in Whom Breast Cancer Surgery Can Be Eliminated Following Neoadjuvant Systemic Therapy.
    Kuerer HM; Rauch GM; Krishnamurthy S; Adrada BE; Caudle AS; DeSnyder SM; Black DM; Santiago L; Hobbs BP; Lucci A; Gilcrease M; Hwang RF; Candelaria RP; Chavez-MacGregor M; Smith BD; Arribas E; Moseley T; Teshome M; Miggins MV; Valero V; Hunt KK; Yang WT
    Ann Surg; 2018 May; 267(5):946-951. PubMed ID: 28549010
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vacuum-Assisted Breast Biopsy After Neoadjuvant Systemic Treatment for Reliable Exclusion of Residual Cancer in Breast Cancer Patients.
    Koelbel V; Pfob A; Schaefgen B; Sinn P; Feisst M; Golatta M; Gomez C; Stieber A; Bach P; Rauch G; Heil J
    Ann Surg Oncol; 2022 Feb; 29(2):1076-1084. PubMed ID: 34581923
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prediction of pathologic complete response using image-guided biopsy after neoadjuvant chemotherapy in breast cancer patients selected based on MRI findings: a prospective feasibility trial.
    Lee HB; Han W; Kim SY; Cho N; Kim KE; Park JH; Ju YW; Lee ES; Lim SJ; Kim JH; Ryu HS; Lee DW; Kim M; Kim TY; Lee KH; Shin SU; Lee SH; Chang JM; Moon HG; Im SA; Moon WK; Park IA; Noh DY
    Breast Cancer Res Treat; 2020 Jul; 182(1):97-105. PubMed ID: 32418044
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Minimally Invasive Complete Response Assessment of the Breast After Neoadjuvant Systemic Therapy for Early Breast Cancer (MICRA trial): Interim Analysis of a Multicenter Observational Cohort Study.
    van Loevezijn AA; van der Noordaa MEM; van Werkhoven ED; Loo CE; Winter-Warnars GAO; Wiersma T; van de Vijver KK; Groen EJ; Blanken-Peeters CFJM; Zonneveld BJGL; Sonke GS; van Duijnhoven FH; Vrancken Peeters MTFD
    Ann Surg Oncol; 2021 Jun; 28(6):3243-3253. PubMed ID: 33263830
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identifying pathologic complete response of the breast after neoadjuvant systemic therapy with ultrasound guided biopsy to eventually omit surgery: Study design and feasibility of the MICRA trial (Minimally Invasive Complete Response Assessment).
    van der Noordaa MEM; van Duijnhoven FH; Loo CE; van Werkhoven E; van de Vijver KK; Wiersma T; Winter-Warnars HAO; Sonke GS; Vrancken Peeters MTFD
    Breast; 2018 Aug; 40():76-81. PubMed ID: 29698928
    [TBL] [Abstract][Full Text] [Related]  

  • 12. RESPONDER - diagnosis of pathological complete response by vacuum-assisted biopsy after neoadjuvant chemotherapy in breast Cancer - a multicenter, confirmative, one-armed, intra-individually-controlled, open, diagnostic trial.
    Heil J; Sinn P; Richter H; Pfob A; Schaefgen B; Hennigs A; Riedel F; Thomas B; Thill M; Hahn M; Blohmer JU; Kuemmel S; Karsten MM; Reinisch M; Hackmann J; Reimer T; Rauch G; Golatta M
    BMC Cancer; 2018 Aug; 18(1):851. PubMed ID: 30144818
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Can axillary surgery be omitted in patients with breast pathologic complete response after neoadjuvant systemic therapy for breast cancer? A real-world retrospective study in China.
    Chen R; Li S; Li Y; Zhu Q; Shi X; Xu L; Xu Y; Zhang W; Huang X; Wang J; Zha X
    J Cancer Res Clin Oncol; 2021 Dec; 147(12):3495-3501. PubMed ID: 34398298
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Accuracy of Magnetic Resonance Imaging-Guided Biopsy to Verify Breast Cancer Pathologic Complete Response After Neoadjuvant Chemotherapy: A Nonrandomized Controlled Trial.
    Sutton EJ; Braunstein LZ; El-Tamer MB; Brogi E; Hughes M; Bryce Y; Gluskin JS; Powell S; Woosley A; Tadros A; Sevilimedu V; Martinez DF; Toni L; Smelianskaia O; Nyman CG; Razavi P; Norton L; Fung MM; Sedorovich JD; Sacchini V; Morris EA
    JAMA Netw Open; 2021 Jan; 4(1):e2034045. PubMed ID: 33449096
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnosing Pathologic Complete Response in the Breast After Neoadjuvant Systemic Treatment of Breast Cancer Patients by Minimal Invasive Biopsy: Oral Presentation at the San Antonio Breast Cancer Symposium on Friday, December 13, 2019, Program Number GS5-03.
    Heil J; Pfob A; Sinn HP; Rauch G; Bach P; Thomas B; Schaefgen B; Kuemmel S; Reimer T; Hahn M; Thill M; Blohmer JU; Hackmann J; Malter W; Bekes I; Friedrichs K; Wojcinski S; Joos S; Paepke S; Ditsch N; Rody A; Große R; van Mackelenbergh M; Reinisch M; Karsten M; Golatta M;
    Ann Surg; 2022 Mar; 275(3):576-581. PubMed ID: 32657944
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Minimally Invasive Breast Biopsy After Neoadjuvant Systemic Treatment to Identify Breast Cancer Patients with Residual Disease for Extended Neoadjuvant Treatment: A New Concept.
    Pfob A; Cai L; Schneeweiss A; Rauch G; Thomas B; Schaefgen B; Kuemmel S; Reimer T; Hahn M; Thill M; Blohmer JU; Hackmann J; Malter W; Bekes I; Friedrichs K; Wojcinski S; Joos S; Paepke S; Degenhardt T; Rom J; Rody A; van Mackelenbergh M; Banys-Paluchowski M; Große R; Reinisch M; Karsten MM; Sidey-Gibbons C; Wallwiener M; Golatta M; Heil J
    Ann Surg Oncol; 2024 Feb; 31(2):957-965. PubMed ID: 37947974
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Axillary lymph node dissection versus radiotherapy in breast cancer with positive sentinel nodes after neoadjuvant therapy (ADARNAT trial).
    Garcia-Tejedor A; Ortega-Exposito C; Salinas S; Luzardo-González A; Falo C; Martinez-Pérez E; Pérez-Montero H; Soler-Monsó MT; Bajen MT; Benitez A; Ortega R; Petit A; Guma A; Campos M; Plà MJ; Pernas S; Peñafiel J; Yeste C; Gil-Gil M; Guedea F; Ponce J; Laplana M
    Front Oncol; 2023; 13():1184021. PubMed ID: 37621686
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MINImal vs. MAXimal Invasive Axillary Staging and Treatment After Neoadjuvant Systemic Therapy in Node Positive Breast Cancer: Protocol of a Dutch Multicenter Registry Study (MINIMAX).
    de Wild SR; Simons JM; Vrancken Peeters MTFD; Smidt ML; Koppert LB;
    Clin Breast Cancer; 2022 Jan; 22(1):e59-e64. PubMed ID: 34446364
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tailored axillary surgery with or without axillary lymph node dissection followed by radiotherapy in patients with clinically node-positive breast cancer (TAXIS): study protocol for a multicenter, randomized phase-III trial.
    Henke G; Knauer M; Ribi K; Hayoz S; Gérard MA; Ruhstaller T; Zwahlen DR; Muenst S; Ackerknecht M; Hawle H; Fitzal F; Gnant M; Mátrai Z; Ballardini B; Gyr A; Kurzeder C; Weber WP
    Trials; 2018 Dec; 19(1):667. PubMed ID: 30514362
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trends in use of neoadjuvant systemic therapy in patients with clinically node-positive breast cancer in Europe: prospective TAXIS study (OPBC-03, SAKK 23/16, IBCSG 57-18, ABCSG-53, GBG 101).
    Tausch C; Däster K; Hayoz S; Matrai Z; Fitzal F; Henke G; Zwahlen DR; Gruber G; Zimmermann F; Andreozzi M; Goldschmidt M; Schulz A; Maggi N; Saccilotto R; Heidinger M; Mueller A; Tampaki EC; Bjelic-Radisic V; Sávolt Á; Smanykó V; Hagen D; Müller DJ; Gnant M; Loibl S; Markellou P; Bekes I; Egle D; Ruhstaller T; Muenst S; Kuemmel S; Vrieling C; Satler R; Becciolini C; Bucher S; Kurzeder C; Simonson C; Fehr PM; Gabriel N; Maráz R; Sarlos D; Dedes KJ; Leo C; Berclaz G; Fansa H; Hager C; Reisenberger K; Singer CF; Montagna G; Reitsamer R; Winkler J; Lam GT; Fehr MK; Naydina T; Kohlik M; Clerc K; Ostapenko V; Lelièvre L; Heil J; Knauer M; Weber WP
    Breast Cancer Res Treat; 2023 Sep; 201(2):215-225. PubMed ID: 37355526
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.